Jeffrey Lawrence Schwartz Sells 3,890 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Jeffrey Lawrence Schwartz sold 3,890 shares of Kestra Medical Technologies stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $25.18, for a total transaction of $97,950.20. Following the completion of the sale, the director owned 7,019 shares in the company, valued at approximately $176,738.42. This represents a 35.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

Shares of NASDAQ:KMTS traded down $0.50 during mid-day trading on Thursday, reaching $23.57. The stock had a trading volume of 310,496 shares, compared to its average volume of 240,413. The business’s 50 day moving average price is $25.42 and its 200 day moving average price is $22.71. Kestra Medical Technologies, Ltd. has a 1 year low of $17.34 and a 1 year high of $30.00. The company has a market cap of $1.38 billion, a P/E ratio of -9.74 and a beta of 0.62. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million for the quarter. Research analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on KMTS shares. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating on the stock. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 31st. JPMorgan Chase & Co. began coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, BTIG Research restated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.14.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of KMTS. Russell Investments Group Ltd. raised its stake in Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after buying an additional 474 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. acquired a new position in Kestra Medical Technologies during the 4th quarter valued at about $72,000. Brown Brothers Harriman & Co. boosted its holdings in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new position in shares of Kestra Medical Technologies in the second quarter valued at about $93,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.